AstraZeneca vs BNP Paribas: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and BNP Paribas side by side

1. 1848BNP Paribas

   Comptoir national d'escompte de Paris founded

   Created by decree in March 1848 to restart commercial credit after the February Revolution, with capital from private subscribers, the City of Paris and the State. It is the oldest root of the BNP side of the group.

2. 1860BNP Paribas

   First overseas branches in Shanghai and Calcutta

   The Comptoir opened branches in Shanghai and Calcutta, becoming the first French bank to build a branch network abroad from scratch, later adding Hong Kong, London, San Francisco and Sydney.

3. 1872BNP Paribas

   Banque de Paris et des Pays-Bas formed

   The Banque de Paris, founded in 1869, merged on 27 January 1872 with Louis-Raphaël Bischoffsheim's Amsterdam-based Nederlandsche Credit- en Deposito Bank to create the investment bank later known as Paribas.

4. 1889BNP Paribas

   Comptoir rescued after the copper crash

   Losses on industrialist Eugène Secrétan's attempt to corner the copper market forced the Comptoir d'escompte de Paris into liquidation, backed by a 100-million-franc Banque de France advance. It was refounded in June 1889 as a deposit bank.

5. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

6. 1966BNP Paribas

   Banque Nationale de Paris created

   Finance minister Michel Debré merged the state-owned CNEP and Banque nationale pour le commerce et l'industrie (BNCI) to form Banque Nationale de Paris (BNP).

7. 1982BNP Paribas

   Paribas nationalised

   The Mauroy government nationalised Paribas, which adopted its telegraph address, Paribas, as its brand that year.

8. 1987BNP Paribas

   Paribas privatised

   The Chirac government returned Paribas to private ownership in January 1987.

9. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

10. 1993BNP Paribas

    BNP privatised

    BNP was privatised in October 1993 under chairman Michel Pébereau.

11. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

12. 1999BNP Paribas

    Three-way takeover battle

    Société Générale bid for Paribas, and BNP answered with offers for both banks. BNP won control of Paribas but failed to take Société Générale.

13. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

14. 2000BNP Paribas

    BNP Paribas created

    The merger of BNP and Paribas was completed in May 2000, combining BNP's retail network with Paribas's investment banking.

15. 2001BNP Paribas

    Full ownership of BancWest

    BNP Paribas agreed to buy the 55% of BancWest, parent of Bank of the West and First Hawaiian Bank, that it did not already own for about $2.45 billion. The Federal Reserve approved the deal on 4 December 2001.

16. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

17. 2006BNP Paribas

    BNL acquired in Italy

    BNP Paribas bought Banca Nazionale del Lavoro, making Italy its second domestic retail market.

18. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

19. 2009BNP Paribas

    Fortis Bank acquired in Belgium

    In May 2009 BNP Paribas took control of Fortis Bank, now BNP Paribas Fortis, paying with new shares issued to the Belgian state and the Grand Duchy of Luxembourg. It also bought 25% of AG Insurance for ~$1.55 billion (€1.375 billion).

20. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

21. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

22. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

23. 2014BNP Paribas

    US sanctions guilty plea

    BNP Paribas pleaded guilty in New York and agreed to pay about $8.9 billion for processing dollar transactions for Sudan, Iran and Cuba in breach of US sanctions.

24. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

25. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

26. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

27. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

28. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

29. 2023BNP Paribas

    Bank of the West sold to BMO

    BNP Paribas completed the $16.3 billion cash sale of Bank of the West to BMO Financial Group on 1 February 2023, leaving US retail banking.

30. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

31. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

32. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

33. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

34. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

35. 2025BNP Paribas

    AXA Investment Managers acquired

    BNP Paribas Cardif completed the ~$5.76 billion (€5.1 billion) purchase of AXA IM on 1 July 2025 and signed a long-term partnership to manage a large part of AXA's assets.

36. 2025BNP Paribas

    Sudan jury verdict

    A Manhattan federal jury found BNP Paribas liable to three Sudanese refugees in October 2025 and awarded $20.75 million. The bank is appealing.

37. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

38. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

39. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

40. 2026BNP Paribas

    Ageas partnership reset

    On 28 April 2026 BNP Paribas Fortis sold its 25% of AG Insurance to Ageas for ~$2.15 billion (€1.9 billion) and renewed their Belgian bancassurance partnership, while Cardif raised its Ageas stake to 22.5%.

41. 2026BNP Paribas

    Arval completes Athlon purchase

    Arval completed its purchase of Athlon from Mercedes-Benz Group on 31 July 2026, reaching a combined fleet of 2.3 million vehicles.

Acquisitions

Questions about AstraZeneca vs BNP Paribas